Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective—: A prevailing concept is that high-density lipoprotein (HDL) is secreted into the systemic circulation as a small mainly discoidal particle, which expands progressively and becomes spherical by uptake and esterification of cellular cholesterol and then contracts by cholesterol ester delivery to the liver, a process known as reverse cholesterol transport, thought to be impaired in people with low HDL cholesterol (HDLc). This metabolic framework has not been established in humans. Approach and Results—: We studied the metabolism of apolipoprotein A-I in 4 standard HDL sizes by endogenous isotopic labeling in 6 overweight adults with low HDLc and in 6 adults with normal body weight with high plasma HDLc. Contrary to expectation, HDL was secreted into the circulation in its entire size distribution from very small to very large similarly in both groups. Very small (prebeta) HDL comprised only 8% of total apolipoprotein A-I secretion. Each HDL subfraction circulated mostly within its secreted size range for 1 to 4 days and then was cleared. Enlargement of very small and medium to large and very large HDL and generation of very small from medium HDL were minor metabolic pathways. Prebeta HDL was cleared slower, whereas medium, large, and very large HDL were cleared faster in the low HDLc group. Conclusions—: A new model is proposed from these results in which HDL is metabolized in plasma mainly within several discrete, stable sizes across the common range of HDLc concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870 · cited 1×
“Intricate molecular machinery has evolved to maintain homeostasis of cellular cholesterol content by the actions of HDL.(8,10,11,13,14) The current canonical framework for HDL metabolism begins with secretion into plasma of nascent very small discoidal HDL (prebeta-1) that has a low content of unesterified cholesterol…”
BackgroundGenetic Variant of the Scavenger Receptor BI in Humans
Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317
Brinton, E. A., Eisenberg, S., & Breslow, J. L. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.707 · Cited by 265
THOMPSON, A., & DANESH, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01644.x · Cited by 252 · cited 1×
“156 The high-density lipoprotein (HDL) level, quantified by the concentration of its cholesterol component, that is, HDL cholesterol level (HDLc), or its apolipoprotein A-I (apoA-I) level, is indisputably an independent risk factor for coronary heart disease (CHD) based on meta-analysis or pooling of many prospective…”
BackgroundHorowitz, B. S., Goldberg, I. J., Merab, J., Vanni, T. M., Ramakrishnan, R., & Ginsberg, H. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116384 · Cited by 231
Cited by
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
“Recent proteomic analyses and metabolic turnover studies provided evidence that distinct HDL sub-classes have a pre-defined core-protein composition that remains relatively stable throughout their lifecycle.(56,57) Interestingly, these HDL sub-classes frequently contain specialized proteins that fulfil related or comp…”
BackgroundThe dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
The impact of aerobic exercise on HDL quantity and quality: a narrative review
Franczyk, B., Gluba-Brzózka, A., Ciałkowska-Rysz, A., Ławiński, J., & Rysz, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054653 · Cited by 142
Didichenko, S. A., Navdaev, A. V., Cukier, A. M. O., Gille, A., Schuetz, P., Spycher, M. O., Thérond, P., Chapman, M. J., Kontush, A., & Wright, S. D. (2016) · Circulation Research · doi:10.1161/circresaha.116.308685 · Cited by 106
Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Self-citation
Metadata
- Authors
- Mendivil, C. O., Furtado, J., Morton, A. M., Wang, L., & Sacks, F. M.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-01
- Volume
- 36
- Issue
- 1
- Pages
- 156-165
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2177021195
- Cited by
- 74
- References
- 15
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans. https://app.cochat.ai/papers/10.1161/atvbaha.115.306138
- The paper
- Mendivil, C. O., Furtado, J., Morton, A. M., Wang, L., & Sacks, F. M. (2016). Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.115.306138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.